NeoGenomics, Inc. announced that as part of the on-going restructuring efforts, the executive position of President, Advanced Diagnostics is being eliminated and as a result, Vishal Sikri, the current President, Advanced Diagnostics, will no longer hold such role and will no longer be a named executive officer. The effective date of the change is still being determined by the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.7 USD | -1.37% | -3.99% | -8.62% |
May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
Apr. 30 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.62% | 1.9B | |
-22.04% | 8.54B | |
+68.69% | 4.32B | |
-0.82% | 2.53B | |
-39.22% | 2.48B | |
-18.63% | 1.59B | |
-40.70% | 1.23B | |
+13.38% | 1.13B | |
+16.15% | 994M | |
-4.52% | 921M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics